UK Markets open in 3 hrs 28 mins
  • NIKKEI 225

    28,747.69
    -811.41 (-2.75%)
     
  • HANG SENG

    29,118.30
    -762.12 (-2.55%)
     
  • CRUDE OIL

    61.71
    +0.43 (+0.70%)
     
  • GOLD FUTURES

    1,708.30
    -7.50 (-0.44%)
     
  • DOW

    31,270.09
    -121.41 (-0.39%)
     
  • BTC-GBP

    35,700.95
    +506.80 (+1.44%)
     
  • CMC Crypto 200

    995.37
    +7.28 (+0.74%)
     
  • Nasdaq

    12,997.75
    -361.05 (-2.70%)
     
  • ^FTAS

    3,808.24
    +36.56 (+0.97%)
     

Merus to Participate in Upcoming Investor Conferences

Merus N.V.
·1-min read

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in the following investor conferences:

Guggenheim Healthcare Talks 2021 Oncology Days (Fireside chat): Friday, Feb. 12 at 10:30-10:55 a.m. ET

LifeSci Partners Precision Oncology Day (Presentation): Wednesday, Feb. 17 at 10:30-10:55 a.m. ET

2021 SVB Leerink Global Healthcare Conference (Presentation): Friday, Feb. 26 at 8:40-9:10 a.m. ET

The live webcasts of the presentations will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and
https://twitter.com/MerusNV.

CONTACT: Investor and Media Inquiries: Jillian Connell Merus N.V. Investor Relations and Corporate Communications 617-955-4716 j.connell@merus.nl Kathleen Farren Merus N.V. Communications Specialist k.farren@merus.nl